BRISTOL-MYERS INVESTING IN CADUS UP TO $45 MIL FOR SCREENING TECHNOLOGY
Executive Summary
BRISTOL-MYERS INVESTING IN CADUS UP TO $45 MIL FOR SCREENING TECHNOLOGY based on yeast strains. Ac cording to New York City based Cadus Pharmaceutical, advantages of the yeast-based screening system include: isolating novel molecular targets for drug discovery; the ability to measure "the biological activity of a compound, not merely its binding capability"; and quick results, "easy automation and stable storage." A joint committee will supervise research at Cadus and at BMS research facilities in Princeton, NJ., Wallingford, Conn. and Seattle, Wash.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth